Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsKenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
Estimating the term…
The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.
A method for treating multiple myeloma in a subject wherein the subject's cancer cells are resistant to treatment with the proteasome inhibitor PS-341, comprising administering to the subject an effective amount of PS-341 and an effective amount of doxorubicin such that multiple myeloma is treated.
A method for treating multiple myeloma in a subject, wherein the subject's cancer cells are resistant to treatment with the proteasome inhibitor PS-341, comprising administering to the subject an effective amount of PS-341 and an effective amount of doxorubicin such that multiple myeloma is treated, wherein PS-341 is administered at a dose of about 0.001 mg/m2 body surface area/day to about 4.0 mg/m2 body surface area/day.
Dependencies are inferred from the claim text.